This confirmed that targeting SmD2 has cancer-selective therapeutic utility, extending our previous observations on lung cancer cells to multiple solid tumor types and to a larger collection of clinically relevant cell cultures. The gene discussed is SNRPD2; the disease is lung carcinoma.